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The term amorphous calcium phosphate (ACP) has different
meanings. In its first usage ACP refered to amorphous calcium
orthophosphate phases, and the core of this report will essentially
deal with these substances. ACP is also used to refer to micelles of
calcium phosphate (CaP) in milk and cheese, poorly defined do-
mains in apatite ceramics and apatite nanocrystals of biological
or synthetic origin and, sometimes, amorphous calcium polyphos-
phates. The environment of CaP phases in milk has some analogy
with ‘pure’ ACP phases, despite strong interactions with casein,
and will be briefly discussed in this report. Amorphous calcium
polyphosphates are very different substances with concatenated
phosphate groups, and these will not be discussed. Flaws in ceram-
ics made from calcium orthophosphates often correspond to crys-
tal defects and grain boundaries, and again we will not review
these aspects. We include a short review and discussion of amor-
phous domains in nanocrystals, however, such ‘amorphous’ envi-
ronments are rather different in nature from amorphous phases
and a clear distinction has to be established between amorphous
domains associated, for example, with surface structures or grain
boundaries and amorphous phases. The ACP phases covered in this
review are characterised by the absence of any periodic distribu-
tion of atoms.
ACP phases are one of the most frequent forms of CaP minerals
in biological organisms [1]. They have been found, for example, in
the mitochondria of eukaryote and prokaryote cells and ACP has: +33 5 34 32 3499.
ombes).been and is still considered a precursor phase of bone mineral in
vertebrates, although this is highly controversial and is yet to be
clearly established.
The ACP phase is an intermediate phase in the preparation of
several CaPs by precipitation. ACP is present in many biomaterials
and preparations. It is involved, for example, in coatings of metallic
endoprostheses obtained by different techniques, either as a tran-
sitory phase or in the end product. It is used in self-setting inject-
able cements, where it is responsible for the setting reaction. In
addition, ACP is found in several composite materials used in odon-
tology as a remineralising phase for enamel and dentine and its
inclusion in toothpaste formulations as a remineralising agent for
early carious lesions has been proposed.
This short review on amorphous calcium phosphates will first
report on some fundamental aspects related to ACP formation,
composition, structure and physico-chemical properties. The main
physico-chemical techniques used to characterise ACPs will then
be presented. Finally, the different routes of synthesis of ACP and
its main uses in the form of cements, ceramics, composites, coat-
ings and colloidal suspensions for biomedical applications will be
reviewed. Several other reviews have been published that present
different conceptions and aspects of amorphous calcium phos-
phates [1–5].2. Occurrence of ACPs
ACPs occur in many biological systems, especially in primitive
organisms, where they are believed to serve as a reservoir of cal-
cium and phosphate ions. Among the various biogenic amorphous
minerals those mainly constituted of calcium and phosphate are
most abundant in teeth and the exoskeletal structures of marine
invertebrates [6].
Growing interest in ACPs arose in the 1970s, due to the possible
involvement of these compounds in the bone of vertebrates. The
question of its occurrence during bone mineral development, be-
fore final crystallisation of the hydroxyapatite (HA)-like phase,
has led to some discussion and controversy, although it remains
undetectable even at the earliest stage of tissue formation
[2,4,5,7–12]. Until now, the existence of ACPs in vertebrates has
not been demonstrated experimentally except in specific locations,
such as the inner ear structures of embryonic sharks and mamma-
lian milk [2,6]. Based on X-ray radial distribution function analysis
carried out on various bone samples, including those of embryos,
Grynpas et al. concluded, however, that the chemical and struc-
tural changes observed could not be accounted for by the presence
of ACP [9]. Recent works on bone and teeth minerals have sug-
gested the presence of a transient amorphous mineral precursor
and a universal strategy for calcium carbonate-based and CaP-
based biomineralisation in both vertebrates and invertebrates
[10,11,13–15]. Using several techniques, such as Fourier trans-
formed infrared (FTIR) specroscopy, Raman and X-ray absorption
near edge structure (XANES) micro-spectroscopy, high resolution
scanning electron microscopy (SEM) and transmission electron
microscopy (TEM), several authors have recently presented some
evidence of transient ACP in several mineralised tissues such, as
newly formed (outer) murine tooth enamel, newly formed fin
bones of zebrafish and in the early intramembranous mineralisa-
tion of murine calvaria tissue [13–15]. However, because of a lack
of irrefutable proof, the question of the occurrence of an ACP phase
in such newly mineralised tissues of vertebrates remains
unanswered.
In addition, characterising the first formed mineral deposits
(transient amorphous mineral phases) in a tissue without altering
them during sample preparation and/or analysis (for example by
dehydration, irradiation or the use of solvents) is challenging. Such
protocols can lead to the dehydration of nanocrystals and loss of
their hydrated surface structure, which might be transformed into
amorphous-like domains. In contrast, other analyses on wet and/or
poorly preserved samples can lead to the conversion of amorphous
phases into more stable apatite or octacalcium phosphate (OCP)
phases.
Complementing these works related to biogenic ACP as a tran-
sient mineral phase, we can also find in the literature several
in vitro studies on the precipitation of CaPs from electrolyte solu-
tion, contributing to our understanding of the formation of CaP
biominerals [16–19]. The authors set-up in vitro conditions allow-
ing ACP formation as a transient phase; ions and/or proteins in-
volved in biomineralisation can be introduced into such in vitro
model solutions or systems.3. Different ACPs
The literature provides many references to different ACPs,
essentially distinguishable by their Ca/P atomic ratio.
Amorphous tricalcium phosphate (ATCP), with an atomic Ca/P
ratio of 1.5 and the chemical formula (I) Ca3(PO4)2nH2O, is most
widely found in amorphous precipitates obtained in alkaline media
(pH range 9–11). This composition corresponds to a well-defined
compound and also seems to be found in ACP formed at high tem-
perature. In fact, in the absence of mineral ions other than Ca2+ and
PO43 the composition of ACP is restrained to chemical formula (I)
for charge balance reasons.
In more acidic solutions ACPs can contain HPO42 ions instead
of PO43, leading to a lower Ca/P ratio. Ratios as low as 1.15 have
been obtained, however, such phases are unstable and convert veryrapidly into dicalcium phosphate dihydrate (DCPD) (CaH-
PO42H2O). A second ‘stable’ ACP, termed ACP2, has been proposed
by Christoffersen et al. to explain the initial variation in pH of a
solution during the transformation of ACP into crystalline CaP
phases, such as OCP and calcium-deficient apatite [16]. Based on
TEM analysis, ACP2 was identified as a separate amorphous phase
with a floccular morphology and no electron diffraction pattern,
compared with the spherular morphology of the first amorphous
phase (ACP1). In experiments at 30 and 42 C the Ca/P ratio of
the early formed solid phases in solutions varied between 1.35
and 1.38.
In non-aqueous or ethanol–water media ACP phases with a
much lower Ca/P ratio than composition (I) can be obtained, corre-
sponding, for example, to amorphous OCP [Ca8H2(PO4)4nH2O] or
amorphous dicalcium phosphate (DCP) (CaHPO4) [20–22]. The
preparation of these ACP phases will be detailed in the synthesis
of ACPs section of this paper.
ACP phases with a Ca/P ratio higher than 1.5 can only be ob-
tained in the presence of foreign ions, most frequently carbonate
and oxide ions. This is the case, for example, of ACP phases formed
during plasma spraying of HA, which can contain oxide ions. Many
other foreign ions may be incorporated into ACPs, and in these
cases consideration of the Ca/P ratio to describe the ACP phase
has no meaning.
However, the composition of even the most frequent form of
ACP, i.e. ATCP, can change on ageing. According to Heughebaert,
internal hydrolysis can occur in ATCP gels, leading to the formation
of HPO42and OH ions [23,24]:
H2Oþ PO43 ! HPO42 þ OH ð1Þ
This leads to a range of compositions represented as:
Ca9ðPO4Þ6xðHPO4ÞxðOHÞx
This reaction would precede the crystallisation of calcium-deficient
apatite, considered to occur when x = 1. Evidence for the existence
of HPO42and OH ions in ATCP has been recently provided using
solid-state nuclear magnetic resonance (NMR) [25].
The present review paper reports studies mainly related to the
most frequent form of ACP, i.e. ATCP.4. Structure of ACP
The structure of ATCP was first determined by Betts and Posner
based on the radial distribution function [26,27]. A short range or-
der was evidenct in ATCP, corresponding to Ca9(PO4)6 units with an
average diameter of 0.95 nm, often referred as ‘Posner’s clusters’.
These clusters correspond to a local arrangement of calcium and
phosphate ions existing in the structure of apatites. It was later
suggested that these clusters in fact possessed a S6 symmetry. A
representation of the Posner’s cluster is given in Fig. 1a [28]. This
arrangement is analogous to that existing in several other crystal-
line phosphates, such as apatites, OCP and b-tricalcium phosphate
(TCP); the relationship between the original Posner’s cluster and
apatite structure is represented in Fig. 1b. Theoretical investiga-
tions of the stability of different calcium and phosphate clusters
with an increasing number of ions have confirmed that Posner’s
clusters are the most stable arrangement [29]. Analogous arrange-
ments have been found in intracellular biological calcified tissues
and in high temperature ACP obtained from plasma spraying HA,
although it has been suggested that larger clusters could exist
[30,31]. The formation of Posner’s clusters has been established
for ATCP and supposes that there is no HPO42 in the ACP. The ef-
fect of HPO42 ions on the structure of Posner’s clusters is un-
known, as is the effect of biologically relevant foreign ions like
carbonate, magnesium and pyrophosphate. Recent ab initio calcu-
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Fig. 1. Structure of the amorphous calcium phosphate. (a) Representation of Posner’s cluster with a S6 symmetry according to Treboux et al. [28]. Three calcium ions are
superimposed, forming a column on the C3 axis of the figure located at z = 0, 1/2 and 1. Two other groups of three calcium ions are at the periphery of the cluster at z = 3/4 and
z = 1/4 positions. Phosphorus atoms of phosphate groups are at z = 1/2 position, with two of the oxygen atoms of the phosphate tetrahedrons. The global chemical
composition corresponds to Ca9(PO4)6. (b) Original model of Posner’s cluster showing its relationship with the apatite structure.lations suggest that Posner’s clusters with six protons and six OH
ions are stable, although such structures with a Ca9(HPO4)6(OH)6
composition have never been experimentally found [32].
Other investigations of the environments of ions in ATCP have
been made by solid-state NMR and FTIR or Raman spectroscopy
and will be discussed in the appropriate section.
The environment of calcium ions in ACP has also been investi-
gated by extended X-ray absorption fine structure (EXAFS) spec-troscopy and the data obtained seem in agreement with the
model proposed by Posner [33].
The arrangements of clusters into larger structures are not well
known. In fact, precipitated ATCP contains a large amount of water,
considered to be present in part in the inter-cluster space, allowing
the association of Posner’s clusters into larger spherical units of
20–300 nm diameter [3]. A second type of water, more loosely
bound, would be simply adsorbed onto these units. It has been
shown that spherical associations were preceded by disk-shaped
associations corresponding to gel-like flocculates progressively
transforming over time into more stable spherical units [34]. The
morphology of ACP is still used as a distinctive feature to detect
this phase in various systems, although it appears insufficient.
Determination of the specific surface area of ATCP generally
leads to surprisingly low numbers. This is related to the larger
spherical associations of Posner’s clusters and the apparent hin-
drance to nitrogen adsorption of these inner surfaces [35,36].5. Physico-chemical properties of ACP
5.1. Solubility
Determination of the solubility of ACP is a delicate problem and
several different solubility products have been proposed, essen-
tially concerning ATCP (Table 1). Some of these solubility products
are lower than that of crystalline a-TCP and seem erroneous as the
free-energy of formation of a crystalline substance is generally
lower than that of an amorphous one with the same composition,
which thus should lead to a higher solubility of the amorphous
phase, which is generally found. One reason for these discrepancies
is the instability of ACP and its propensity to crystallise into apatite
or other phases, although Meyer and Eanes have shown that the
ion activity product of ACP in aqueous solution remained constant
over a long period and for a large range of pH values [2,37]. A sec-
ond difficulty is related to the initial composition of ACP, especially
its HPO42 ion content or that of other ionic impurities such as
Mg2+ and CO32 ions, which are not usually reported. A last identi-
fied difficulty is the change in composition of ACP on ageing and
the development of internal hydrolysis without any apparent
structural change.
The best experimental approach to determining the solubility
product of ATCP uses recent preparations with a large solid/solu-
tion ratio to reach a rapid solubility equilibrium before hydrolysis
occurs.5.2. Thermal stability
Unlike solubility, the thermal stability of ATCP is well docu-
mented. On heating ATCP first loses water. Two types of water loss
occur, corresponding to loosely bound water molecules adsorbed
on the surface of ATCP agglomerates and more strongly bound in-
ter-cluster water molecules, respectively. The first loss is essen-
tially reversible, whereas the second is mostly irreversible [46,47].Table 1
Solubility products of ATCPs compared with those of a-TCP, b-TCP and two ACPs with
Ca/P = 1.35.
Type of ACP
(conditions)
Solubility product
[–log(Ksp)]
[calculated for
Ca3(PO4)2]
References and observations
ATCP (20 C) 25.2 [37]
ACP 1a (Ca/
P = 1.35)
25.5 [38] (32% of total P as HPO42)
ACP 2a (Ca/
P = 1.35)
28.3 [38] (32% of total P as HPO42)
ATCP (25 C, pH
7–9)
25.5 [39] (from the abstract, with 4% of
total P as HPO42)
ATCP (18 ± 3 C) 26.5 [40]
ATCP 24.8 [41]
ATCP (25 C) 25.7 [42]
ATCP (25 C) 23.9 [43] (with 0.52 wt.% CO32)
b-TCP 28.9 [44]
a-TCP 25.5 [45]
a These ACP differed in their ageing times.Lyophilised precipitated ATCP crystallises into a-TCP at 630 C.
The initial formation of a metastable high temperature form when
crystallisation of an amorphous compound occurs has been re-
ported in many other systems. This phenomenon is known as ‘Ost-
wald’s step rule’ or the law of successive reactions. In any
crystallisation process the generally observed state is not the most
stable state but the least stable state that is closest in terms of free
energy change to the original state [48]. High temperature ACP
crystallises generally at a higher temperature (around 700 C) lead-
ing, according to Feng et al., to a mixture of HA, tetracalcium phos-
phate (TTCP) and CaO [49]. Ranz observed that recrystallisation of
high temperature ACP leads to HA in the presence of water vapour
and oxyapatite in vacuum [31]. In any case, a-TCP has been re-
ported as a transitory phase, unlike low temperature ATCP.
Differential thermogravimetric analysis (DTA) and differential
scanning calorimetry (DSC) studies show a narrow exothermic
crystallisation peak, which can be used to estimate the amount
of ACP in mixtures with apatite or other compounds. This crystal-
lisation point is sensitive to the presence of impurities: it moves
towards higher temperatures in the presence of carbonate, mag-
nesium or pyrophosphate ions (the three major ionic stabilisers
of ACP). This displacement is associated with a broadening of
the exothermic peaks, which might possibly become difficult to
observe [23].
5.3. Evolution in aqueous media
ACP is converted into hydroxylated apatite in aqueous media.
This reaction has been studied in suspensions and gel-like states,
on just precipitated wet samples and on lyophilised and heated
powders [2,23,24,50,51]. Some common features can be distin-
guished: an induction period is generally observed during which
the amorphous state is preserved; crystallisation then occurs
rather rapidly and follows a sigmoid evolution [51]; the conversion
of ATCP to apatite is ‘autocatalytic’, i.e. in the presence of apatite
seeds the induction period is no longer observed and conversion
is more rapid; in most conversion reactions occurring at physiolog-
ical pH the apatite obtained is hydroxylated, calcium-deficient and
contains hydrogen phosphate species. Several differences can be
observed depending on the initial state of the ACP.
5.3.1. Conversion in the gel-like state
Heughebaert et al. and Guégan distinguished two events in the
hydrolysis of ATCP gels: a microcalorimetric analysis curve for ACP
conversion to apatite at 25 C is presented in Fig. 2 [23,24,51]. TheFig. 2. Microcalorimetric analysis of the conversion of ACP gel into apatite at 25 C
[51]. A broad endothermal peak corresponding to the hydrolysis of PO43 ions is
superimposed on a narrow exothermal peak corresponding to the crystallisation of
apatite.
first event is ‘internal’ hydrolysis of PO43 ions producing HPO42
and OH ions (see Eq. (1) above) associated with an endothermic
reaction giving a rather broad line. The second event is crystallisa-
tion, corresponding to a rather narrow exothermic peak. These data
can be used to determine the progress of both reactions with time,
considered to correspond to the ratio of the area under the differ-
ent curves at time t versus the overall area of the thermal events.
The progress of such reactions can also be followed and deter-
mined using chemical analysis of HPO42 ions and X-ray diffraction
analysis (for apatite content), as presented in Fig. 3, distinguishing
the slow hydrolysis reaction and the fast crystallisation process.
The kinetics of the hydrolysis and crystallisation reactions have
been shown to follow [51] a = kt + c, where a is the progress of the
reaction (hydrolysis of PO43 or crystallisation), k is a kinetic con-
stant following Arrhenius law and c is a constant depending on the
initial state of the precipitate, especially the initial content of
HPO42. The initial composition thus appears to be an important
parameter in the conversion reaction, one which has often been
neglected and may possibly explain most of the divergence be-
tween authors.
According to Heughebaert, crystallisation is related to the
hydrolysis of PO43 and occurs when one-sixth of the PO43 has
been transformed into HPO42, which also corresponds to occu-
pancy of half of the OH sites in the apatite unit cell and the chem-
ical formula [24]:
Ca9ðPO4Þ5ðHPO4ÞðOHÞ:
The activation energy of these reactions can then be determined
(25.2 kcal mol1). For the autocatalytic effect experiments by Gué-
gan using apatite seeds have shown that crystallisation spreads
from the point where the apatite seeds were introduced [51].
5.3.2. Conversion in aqueous suspensions
Several works have investigated conversion in solution
[2,50,52,54] and the effect of factors such as the pH, temperature
and the presence of foreign ions.
In a detailed investigation at different pH values (6.8–10) Bos-
key and Posner [50] showed that the conversion rate was consider-
ably slower at alkaline pH (about 5 h at pH 9). In fact, ATCP is
generally precipitated in alkaline media and sometimes even
washed with an alkaline (ammonia containing) solution to prevent
any alteration during filtration and washing [23,37]. As the pH be-4 6 8 10 12 14 16 18 20 22 24 26
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Fig. 3. Conversion of ATCP in gel form. Comparison of the advancement of the
hydrolysis of PO43 obtained from chemical analysis of HPO42 (squares) with the
advancement of crystallization obtained by XRD analysis (intensity of the 002 peak
of apatite) (circles) [51].comes more acidic the conversion rate becomes faster although
some divergence exists, probably related to different experimental
conditions and starting materials. Eanes et al. reported a conver-
sion time of 0.3 h at neutral pH and 25 C, much shorter than the
conversion rate observed for gels (6.5–7 h) by Guégan [51]. At
acidic pH (3–4) the amorphous phases only exist for minutes and
are converted into DCPD instead of apatite. It seems, however, that
at very alkaline pH (12.8), the conversion time was again shorter
(<1 h) [52].
The hydrolysis of ATCP has been shown to be temperature
dependent [50]. It takes 3 days before crystallisation begins at
10 C, 2 h at 26 C and <30 min at 37 C (pH 8). In the gel form
an analogous evolution is observed and at neutral pH it takes
15 h for complete hydrolysis at 20 C, whereas at 25 C the reac-
tion takes only 7 h [51]. At 37 C hydrolysis is even faster and can
be completed in 20 min in a cement paste [55] (see a more detailed
presentation in Section 8.2.1).
Several compounds or ions can alter the conversion reaction:
mineral ions like Mg2+, Al3+ and Ga3+, carbonate and pyrophosphate
ions which are present in biological media, several organic mole-
cules which can inhibit or delay conversion and other ions such as
fluoride which, in contrast, accelerate conversion [23,54–59].
Several mechanisms have been proposed involving the inhibi-
tion of apatite nucleation and growth, the mobilisation of water
molecules in gels and disorganisation of the cluster assemblies.
5.3.3. Conversion from dry powders
ACPs are generally in the dry state for different applications in
the biomaterial field. Data on the conversion of dry ATCP powders
(lyophilised or heated) into apatite in aqueous media seem to differ
from those obtained with ATCP gels (Fig. 2) or suspensions; the
microcalorimetric curve of lyophilised ACP powder conversion to
apatite at 25 C is presented in Fig. 4 [43]. The endothermal event
can no longer or only barely be detected and instead exothermic
peaks can be observed, corresponding to rehydration of the pow-
ders. The rehydration process occurs in two steps: fast rehydration
of the surface of the ATCP spherules, followed by slow rehydration
of the inter-cluster space within the spherules. The first rehydra-
tion event is not dependent on the temperature of preheating of
the ATCP, but the second process is. The limiting step of the con-
version reaction of dry powders is the slower second rehydration
event.
5.3.4. Conversion mechanisms
Several mechanisms of conversion of ATCP into apatite have
been proposed. For Eanes, dissolution–reprecipitation is the major-0.5 3.5 7.5 11.5 15.5 19.5 23.5 27.5 31.5 35.5
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Fig. 4. Microcalorimetric curve of the conversion of lyophilised ACP powder into
apatite at 25 C. Three events can be distinguished: (1) a sharp exothermal peak
corresponding to wetting of the powder; (2) a broad exothermic peak correspond-
ing to slow rehydration and crystallisation of the amorphous calcium phosphate;
(3) a very small endothermal peak assigned to the hydrolysis of PO43 ions [43].
process, supported by TEM observations of crystal nucleation and
growth on the spherules of ACP [2]. It has been suggested, based
on ionic products in the solution, that at neutral pH OCP is first
formed, which is then converted to apatite through a topotactic
reaction. This process is in accordance with the Ostwald’s step rule.
At alkaline pH, however, the conversion of ATCP leads directly to
hydroxylated apatite. The OCP intermediate phase does not seem
to have been identified under all conversion conditions. This mech-
anism supposes a change in the Ca/P ratio of the solid, which has to
be compensated for either by a change in the Ca/P ratio of the solu-
tion (an increased Ca/P ratio relative to the 1.5 initial value) or the
simultaneous formation of another solid phase with a higher Ca/P
ratio, which could be apatite, however, this phase, which is ther-
modynamically more stable than OCP, would be favoured. Analy-
ses of the solution at the beginning of conversion generally led to
higher Ca/P ratios, in part supporting this mechanism.
Another proposed mechanism is the reorganisation of Posner’s
clusters to build apatite crystals. It is more and more frequently
postulated, with experimental support, that crystals can grow by
the accretion of ion clusters formed in solution instead of individ-
ual ions reaching the surface [60,61]. As apatite-like Posner’s clus-
ters pre-exist in ACP it is conceivable that simple reorganisation of
the clusters could lead to apatite crystals, with a minimum activa-
tion energy requirement [62]. This process would not change the
global chemical composition or the Ca/P ratio as observed, for
example, in the conversion process occurring in gels. In addition,
the conversion reaction is also observed in water–alcohol media,
in which ion dissolution is weak and dissolution–reprecipitation
seems improbable. However, even in gels and water–alcohol media
conversion into apatite generally involves the formation of HPO42
and OH ions. Such changes of composition cannot be accounted
for by a simple reorganisation process.
The third process, proposed by Puech et al. and Guégan, is sur-
face-mediated transformation [51,63]. The hydrolysis of PO43 oc-
curs on the surface of the ATCP agglomerates and leads to the
nucleation of apatite, with crystal growth supported by surface
ion migration. This process seems consistent with observations of
apatite crystal formation, even in the presence of a small amount
of water or in water–alcohol media [63]. In addition, when conver-
sion occurs in solution this process is compatible with incorpora-
tion into the growing apatite crystals of ions from the solution.
Such a conversion process also seems consistent with the observa-
tion that rehydration of powdered ATCP is the limiting step in the
conversion reaction. As the surface layer has different dissolution
properties to the original ATCP precipitate, this conversion mecha-
nism could also be compatible with the observation of a transient
phase based on dissolution behaviour but never detected using dif-
fraction techniques.
At this stage, however, the mechanism of conversion has not yet
been fully elucidated and it seems reasonable to postulate that
competitive processes might occur simultaneously and that their
importance depends essentially on the conversion conditions.
Once apatite or OCP is nucleated, for example, dissolution–repre-
cipitation necessarily occurs, although the progress of this reaction
could be linked to the solid/solution ratio, the temperature of con-
version and the ion diffusion ability of the medium.6. Characterisation of ACP
6.1. Diffraction techniques
The X-ray diffraction (XRD) pattern of ACP is characterised by
several broad diffraction halos, as it can be observed in Fig. 5.
Treatment of the XRD data gives radial distribution functions
(RDFs), presented in Fig. 6, provides several atomic distancesmatching the Posner’s clusters model. The RDFs of ACP disappear
at 0.95 nm, in contrast to that of well-crystallised compounds
such as apatite. This characteristic can be used for the quantita-
tive determination of ACP with a detection limit of 5% [9,64].
The background level in the XRD pattern is commonly used
by ceramicists and polymerists to determine the amorphous
fraction of their materials. It is generally considered that what
does not correspond to the ‘crystalline’ phase in diffractograms
of CaP materials is ‘amorphous’. However, there seems to be
some confusion between non-coherent diffraction domains and
the existence of a real separated amorphous phase. Some CaPs,
especially but not exclusively those with an apatite structure,
can exhibit many different ionic substitutions, defects and
vacancies which can alter the regularity of the atomic array
and cause a considerable increase in the background diffraction
patterns without the involvement of any amorphous phase or
even amorphous domains. Similarly, in nanocrystals the atom ar-
ray can be altered close to the surface, leading to amorphous-
like domains identified by diffraction techniques or spectroscopic
techniques, which should not be confused with the existence of
an amorphous phase because they belong to the crystal. Thus,
there is agreement that the background level in diffractograms
does not really give the amount of ACP phases, but rather repre-
sents irregularities in the periodic distribution of the atoms of
the apatite crystals.6.2. Vibrational spectroscopy
Based on Posner’s clusters with a S6 symmetry and group the-
ory analysis, Somrani et al. predicted several bands in the differ-
ent vibrational domains of the PO4 groups, which are presented
in Table 2 [28,36]. However, these bands are often difficult to
distinguish in the FTIR spectrum of ACP (see Fig. 7) because of
the band superimposition and broadening characteristic of
poorly crystallised and amorphous samples. Resolution enhance-
ment of the spectra has been attempted using mathematical
treatment (self-deconvolution) of the FTIR PO4 bands [36]. The
main characteristic of the FTIR and Raman spectra of ACP is a
m1 PO4 band shifted to 950 cm1, 10 cm1 lower than that of
apatite. This characteristic has been used to distinguish ACP
phases, however, bands at the same position as those of ACP
might also be due to disordered domains arising, for example,
from the drying of surface hydrated layers of poorly crystalline
apatites. Thus, it seems incorrect to attribute these spectroscopic
features to an amorphous phase distinct from nanocrystalline
apatite. The quantitative determination of ACP using FTIR and
Raman spectroscopy does not seem to have been attempted
and, considering the above observations, would seem erroneous
in the absence of other investigations providing evidence for
the presence of a distinct amorphous phase.6.3. Differential thermal analysis
These methods are among the most accurate for the quantita-
tive determination of distinct ACP phases in high and low temper-
ature amorphous phases, including mixtures of ACP and other CaP
phases [43,49]. The principle is very simple: ACP crystallisation is
characterised by a generally rather narrow exothermic peak in
the 600–750 C range. The amount of amorphous phase in a mix-
ture is proportional to the exothermic event. The sensitivity de-
pends on the system considered. For ATCP/HA mixture it is
possible to detect 5% ACP (weight ratio). The sensitivity is, how-
ever, significantly less for ACP samples containing Mg2+ or carbon-
ate ions, due to broadening of the crystallisation peak.
Fig. 5. X-ray diffraction pattern of high temperature amorphous calcium phosphate showing the broad diffraction halos (MoKa).
Fig. 6. Experimental radial distribution function (RDF) of a high temperature amorphous calcium phosphate (bold line) compared with the theoretical RDF of Posner’s
clusters (dotted line) [31]. The size of the experimental clusters appears larger (13 Å) than that of the Posner’s clusters.
Table 2
Theoretical spectra of internal vibrations of phosphate ions in Posner’s clusters
(symmetry S6).
Spectral domain Symmetry species IR and Raman activities
m1 Au, Eu, Ag, Eg 2 IR, 2 Raman
m3, m4 3Au, 3Eu, 3Ag, 3Eg 6 IR, 6 Raman
m2 2Au, 2Eu, 2Ag, 2Eg 4 IR, 4 Raman6.4. Solid-state NMR
Several MAS-NMR spectra of ACP have been published for 1H
and/or 31P [25,65–67].The 31P spectra show only one main very broad band at
3 ppm. relative to H3PO4, consistent with a unique phosphate
site, as proposed in Posner’s model. The position of the very broad
band for ACP is close to that for phosphate ions in apatites
(2.7 ppm) [68].
The 1H spectra of ACP reveal the presence of small amounts of
HPO42 and OH ions undetected by spectroscopic techniques (Ta-
ble 3). It has been suggested that several organised micro-domains,
too small and not numerous enough to give a clear diffraction pat-
tern, could exist in ACP, especially apatite-like domains around the
OH ions and, possibly, water molecules. 1H NMR seems particu-
larly sensitive in detecting faint changes in ACP during ageing [25].
Fig. 7. FTIR spectrum of ACP.Many other techniques have been used to try to characterise
ACP phases.
EXAFS at the K edge of calcium provides spectra particularly
consistent with Posner’s model [33]. XANES of ATCP at the Ca–K
edge gives a specific spectrum (broad singlet) distinct from that
of apatite (doublet of the most intense peak) [69]. However, these
methods cannot be used for the quantification of ACP phases in
mixtures.
7. Synthesis of ACPs
ACPs can be obtained by two main routes: in aqueous medium
at low temperature (wet route) or using high energy processing or
high temperatures (dry route). Depending on the method of the
formation and experimental conditions (solution supersaturation,
pH, etc.), the ACP synthesised can exhibit a Ca/P ratio ranging from
1 to 2 or even higher. The methods of synthesis of ACP presented
hereafter focus on the most commonly known and used ACPs, i.e.
those with a Ca/P ratio of 1.5 or 1.33.
7.1. Wet route synthesis
The wet synthesis route of ACP is based on the double decom-
position of a calcium and phosphate salt in aqueous or water–alco-
hol solutions [23,70,71].
7.1.1. In aqueous medium
ATCP (Ca/P = 1.5) can be prepared by various solution-mediated
routes, usually involving rapid mixing and precipitate filtration.
Most syntheses are at low or room temperature and involve high
supersaturation ratios.
One of the most convenient preparation methods is double
decomposition between aqueous solutions of soluble calcium
and phosphate salts at ambient temperature and at a pH close
to 10 [23,43]. For example, calcium nitrate solution [46.3 g ofTable 3
Positions and assignments of the 1H NMR peaks in ATCPs.
Line positions ( ppm) Attribution
0.2 OH ions in apatite environnent
2.3 Apatite-like channel water
5 Adsorbed water
5.9 Interstitial water (inter-clusters)
7.3 Strongly hydrogen bound water
8–11 HPO42 acidic protons in different environments
11–14 HPO42 acidic protons in different environments
14–17 HPO42 acidic protons in different environmentsCa(NO3)24H2O dissolved in 550 ml of deionised water containing
40 ml of 28 wt.% ammonia solution] was rapidly poured into
stirred ammonium phosphate solution [27.2 g of (NH4)2HPO4 dis-
solved in 1300 ml of deionised water containing 40 ml of 28 wt.%
ammonia solution]. Immediately after precipitation the suspension
was filtered and washed with 3 l of deionised water containing
15 ml of 28 wt.% ammonia solution and finally lyophilised for
72 h [43].
Storage of ACP powders in a freezer is necessary to prevent
conversion and/or phase transformation. Even after drying in a
desiccator or lyophilisator ACP contains a significant proportion
(10–20%) of tightly bound water molecules [71,72]. Dried ACP
can, however, be obtained by heating the powder at 450 C under
vacuum or in air without any discernible differences in the X-ray
diffraction patterns before and after treatment.
ACP can be stabilised, especially in industrial processes, by add-
ing a few per cent Mg2+, pyrophosphate and carbonate ions. When
heated, pyrophosphate and carbonate ions can react to generate
phosphate groups:
P2O7
4 þ CO32 ! 2PO43 þ CO2 " ð2Þ
Dry, heated ATCP is more stable than unheated ACP and can be
stored at room temperature. Generally, ACP is prepared with rela-
tively concentrated solutions and at very high supersaturations
and precipitation is immediate. When the level of supersaturation
is lower an induction period may occur.
The induction period is highly sensitive to several parameters
related to solution composition: a higher initial [Ca]  [P] product
or Ca/P atomic ratio and higher temperature or pH, a lower dielec-
tric constant or the presence of Mg2+, P2O74 or CO32 ions reduced
the time required for induction [4].
The main difficulty encountered in the preparation of ACP is re-
lated to its instability and reactivity in solution, which could limit
reproducibly producing ACP powders by precipitation. As already
mentioned in Section 5.3.2, ACP can be stabilised by the presence
of inorganic ions such as Mg2+, P2O74, CO32 or organic molecules
in the synthesis and/or washing solutions [53,73–75]. For example,
ATCP can be prepared under more acidic conditions (pH  6) and in
the presence of magnesium or citrate ions, known to be inhibitors
of apatite crystal growth [76,77]. LeGeros et al. observed a syner-
gistic effect of a combination of potent apatite crystal growth
inhibitor ions (Mg2+, Zn2+, Fe 2+, P2O74 and CO32) on the forma-
tion of ACP [78,79].
Li and Weng reported an original method to prepare ACP by
precipitation at low temperature (5 C) by adding polyethylene
glycol (PEG) to a calcium solution [80]. They showed that ACP
could be stabilised by PEG in the mother solution for more than
18 h at 5 C and that the Ca/P atomic ratio of the precipitated
ACP could be adjusted between 1.33 and 1.50 by controlling the
pH and initial Ca/P atomic ratio in solution.
In aqueous media ACP is generally obtained at alkaline pH and
the fresh ACP does not contain acid phosphate groups. Under these
conditions ACP shows the composition of TCP with an atomic Ca/P
ratio close to 1.5 [24]. In acidic or neutral solutions the amorphous
phase appears unstable and is rapidly transformed into crystalline
CaP phases such as DCPD, OCP or apatite. This evolution can be de-
layed in water–alcohol solutions to allow ACP with a low Ca/P ra-
tio, containing acidic phosphate groups, to be prepared [81].7.1.2. In water–alcohol or alcoholic media
The presence of ethanol led to a decrease in the dielectric con-
stant favouring the existence of protonated species such as HPO42
[20]. In addition, it has been reported that ethanol stabilises ACP
[82].
Several preparations have been described [20,81,83]. Rodrigues
and Lebugle showed that the presence of ethanol in the precipita-
tion medium influences the composition of the amorphous phase,
especially the HPO42 content and Ca/P ratio [83], and ACPs with
Ca/P ratios close to that of OCP, corresponding to the chemical
composition Ca8(PO4)4(HPO4)2, can be obtained. As for aqueous
preparations, preservation of the amorphous phase is only possible
if the precipitate is dried by lyophilisation and stored in a freezer.
[20].
Layrolle andLebugle reportedanoriginal synthesis route forACPs
using calcium diethoxide [Ca(OEt)2] and orthophosphoric acid
(H3PO4) precipitated in a dry argon atmosphere [21]. Briefly,
Ca(OEt)2 was first prepared in a dry inert atmosphere (argon) by
heating refluxed calcium metal in ethanol for 4 h until it disap-
peared. The orthophosphoric acid solution was then quickly poured
into stirred Ca(OEt)2 solution. After centrifugation and removal of
the supernatant the powder was dried under vacuum at room tem-
perature overnight before storage under argon at –20 C to prevent
crystallisation or hydrolysis. The authors prepared and fully charac-
terised nanosized ACPs of various compositions [amorphous CaH-
PO4, Ca8(PO4)4(HPO4)2 and Ca9(PO4)6] in ethanol simply by varying
the Ca/P ratio of the reactants (1/1, 8/6 and 9/6); theseACPs hadhigh
specific surface areas and reactivities. This ACP sol–gel synthesis
method has also recently been used by Fellah et al. to prepare an
ACP that can be transformed into b-TCP, HA or HA–b-TCP ceramics
after sintering at 1100 C, depending on the initial Ca/P ratio of the
reactants [84].
ACP phases (ACP1 and ACP2) have been observed as intermedi-
ate compounds during the ageing of calcium phosphate precipi-
tated in methanol at room temperature, finally leading to
nanosized b-TCP formation [85].
Finally, an ACP corresponding to an amorphous OCP has been
prepared in 50–50 vol.% water–alcohol medium [81].
7.2. Dry route synthesis
ACP formation can also be prepared by dry methods based on
rapid quenching of melted CaPs or low temperature formation of
CaPs using ion sputtering. These generally lead to phases with var-
iable compositions, sometimes containing impurities, and are not
convenient for the preparation of large amounts of pure ACP. In
the absence of other mineral ions than Ca2+ and PO43 the compo-
sition of the amorphous phase formed is analogous to that of anhy-
drous precipitated ATCP for charge balance reasons [31]. Calcium is
often the only cation, but anions other than phosphate, such as
O2, may also be present in the high temperature amorphous
phase, producing an increase in the Ca/P ratio (>1.5), especially
for ACP in HA plasma sprayed coatings (see Section 8.1.1) [36].
High temperature ACP phases with a lower Ca/P ratio than ATCP
can only result from contamination with other cations or anions,
such as pyrophosphate.
Recently, Yu et al. reported the synthesis of ACP using a dry
mechano-chemical method involving a mixture of DCPD and
Ca(OH)2 reactants with a Ca/P ratio of 1.67 [86]. Other authors have
shown that prolonged high energy ball milling of b-TCP powder in
ethanol or of a ACP and DCPD dry mixture led to amorphous cal-
cium phosphate after 24 h [87,88]. However, there is a non-negli-
gible risk of powder contamination (ball wear) when using this
processing route over extended periods of time to obtain amor-
phous calcium phosphate.
Loher et al. have described a procedure to prepare ACP nanopar-
ticles using a flame spray pyrolysis technique [89]. The precursor
solution was prepared with appropriate amounts of calcium-2-eth-
ylhexanoate and tributyl phosphate to produce a Ca/P ratio in solu-
tion of between 1.43 and 1.67; doping metals such as zinc or
magnesium can also be added to the precursor solution. The pre-cursor mixture is then dispersed in oxygen gas and fed into a meth-
ane/oxygen flame: the burning spray of CaP resulted in flame
synthesis of ACP nanoparticles. The nanoparticles leave the flame
at the top where they are collected on a filter. Fast cooling after for-
mation in the flame prevents crystallisation and leads to ACP nano-
particles (10–50 nm in diameter) with a broad range of
compositions, depending on the Ca/P ratio of the precursor solu-
tion [89], which after calcination led to dicalcium pyrophosphate
(for an initial Ca/P ratio of <1.5) or pure b-TCP (for an initial Ca/P
ratio of 1.52) or HA (for calcium-rich precursor) [89]. However,
high costs are associated with this ACP synthesis route, mainly
due to the high energy flame production and the use of precursors.8. Uses of ACPs in biomaterials
ACPs are involved in numerous biomaterials in the form of coat-
ings, cements, ceramics and composites (Table 4). The presence of
ACP in these biomaterials is in some cases desired and controlled
but in other cases, such as plasma sprayed HA coatings, the amount
cannot be well controlled. Examples found in the literature will be
presented hereafter for each of these kinds of ACP-containing
biomaterials.
8.1. ACPs in coatings
Metals are still and will probably for a long time remain the
main constituents of load bearing prostheses. Efforts have been
made to improve the biological activity of metallic surfaces by
coating them with CaP, with the aim of stabilising the bone–pros-
thesis interface and ensuring early and long-term performance.
ACPs are formed in many coating processes by a low tempera-
ture wet route or a high temperature dry route.
8.1.1. ACPs in high temperature and/or high energy coatings
ACPs occur mainly as a co-product in coatings obtained by high
temperature and/or high energy processing techniques such as
plasma spraying deposition, electrostatic spray deposition (ESD)
and pulsed laser deposition (PLD).
Plasma sprayed HA coatings are the most industrially developed
CaP coatings. ACPs have been found to play a major role in the
mechanical properties of plasma sprayed HA coatings, especially
their adhesion to metal surfaces and biological properties [90–93].
The plasma spraying technique is based on the use of plasma
flames reaching very high temperatures (5000–20,000 C) and high
velocities that project the HA particles onto the surface to be
coated. The individual HA particles are brought to a very high tem-
perature during the short transit time within the flame and are
quenched on the metal surface where they adhere. The CaP coating
obtained mainly comprises HA, but other crystalline and ACP
phases are also present. The amounts of these co-produced phases
are related to the conditions of spraying, such as gas flow, which
controls the time the HA particles spend in the plasma flame, plas-
ma temperature, nature of the gas, cooling conditions and the dis-
tance between the substrate and the flame, along with other
determinant factors such as the quality, density, adsorbed water
and size of the HA particles [94–97].
ACP is always formed in plasma sprayed coatings of CaP phases.
The sprayed HA particles are covered by a fused layer (molten
phase) during their transit in the plasma and ACP formation results
from rapid quenching of this layer on the surface being coated.
The temperature gradient within the HA particles induces an
heterogeneous distribution of the various crystalline and amor-
phous phases within the particles: a schematic representation of
the heterogeneous composition of plasma sprayed HA particles is
shown in Fig. 8 [98,99].
Table 4
Amorphous calcium phosphates in biomaterials.
Type of material Application Main CaP-related effects
Ionic cements Bone substitute Active hardening agents
Dental applications Bioresorbable, surface reactivity
Provider of Ca2+ and PO43 ions
Coatings Coating of metallic
prostheses
Biodegradable and reactive
coating
Mineral–organic
composites
Teeth,enamel
remineralisation
Mechanical properties
Bone substitute Ca and P release in relation with
biological activityAs mentioned in Section 6.1, the presence of an ACP phase is at-
tested to by the existence of a broad band in the X-ray diffraction
diagram of a coating (see Fig. 9). This method is recommended by
standard NF S 94-067 (Materials for surgical implants – qualitative
and quantitative determination of the foreign phases present in
calcium phosphate based powders, deposits and ceramics) to
quantify the ACP content of plasma sprayed HA coatings and their
Ca/P ratios [96–102]. The amount of ACP depends on the coating
conditions and can vary between 20 and 60% in commercial
coatings.
The longevity of a prosthesis very much depends on the bond at
the bone–implant interface and resorption of the coating by the
host organism [93]. ACP should be present on the surface coating
in only moderate quantities because of its fast dissolution, which
promotes fast fixation to bone tissue. However, a minimumMolten phase 
TCP, TTCP, CaO 
Oxyhydroxyapatite 
Fig. 8. Effect of temperature gradient on a plasma sprayed HA particle (from [98]
with the kind permission of Elsevier).
Fig. 9. X-ray diffraction pattern of a plasma sprayed hydroxyapatite coating
showing the different amorphous and crystalline calcium phosphate phases [31].amount of ACP is needed to ensure good adhesion of the coating
to the metallic prosthesis [92,93,103–105].
Plasma sprayed coatings can be subjected to moderate temper-
atures post-treatment to induce ACP crystallisation [105,106].
Other authors have used post-treatment of plasma sprayed HA
coatings with water vapour at 125 C to enhance the conversion
of ACP into crystalline HA [107].
The composition of the amorphous phase is rather imprecise
and seems to vary according to the authors [98,108]. In fact, the
fused layer at the surface of the sprayed particles can partly recrys-
tallise depending on the quenching rate.
The first crystalline phase to form on cooling is calcium oxide,
then calcium tetraphosphate and calcium triphosphate and, finally,
apatite. Thus the composition of the amorphous phase depends on
the respective proportions of the recrystallised phases. Frequently,
CaO forms and the amorphous phase shows a Ca/P ratio lower than
that of the original apatite phase, although it cannot be lower than
1.5 when only Ca2+ and PO43 ions are present for electroneutrality
reasons.
Other high energy coating techniques have been used to coat
metallic substrates with ACP, among which are PLD and ESD
[109,110].
In PLD a pulsed laser beam is focused on a rotating HA target in
a vacuum chamber under a controlled water vapour atmosphere.
Species ejected after each laser pulse reach the surface of the sub-
strate, which can be heated. Several CaP phases can be obtained by
varying the deposition parameters, such as the fluence of the beam
laser, the water vapour pressure and substrate temperature [109].
A 2 lm thick ACP coating was obtained and tested in vitro in
cell culture. After 2 weeks in cell culture bone matrix could be ob-
served covering the sample, but it delaminated after drying of the
sample, indicating poor adhesion and most probably dissolution of
the ACP coating [109,111].
ACP has been deposited on a titanium substrate using the ESD
technique based on the application of a DC voltage (6.3 kV) to gen-
erate a high potential difference between the grounded substrate
holder and nozzle. A solution precursor (calcium and phosphate
in butyl carbitol) and a heated substrate (350 C) were used by Sie-
bers et al. [110]. After 45 min of deposition and an additional heat
treatment at 400 C a 1–2 lm thick ACP coating was obtained;
treatment at higher temperatures led to apatite coatings. The
authors concluded that cell differentiation and proliferation on
ACP-coated samples was equivalent to that on apatite-coated sam-
ples, thereby showing that the crystallinity of a CaP coating depos-
ited by ESD did not affect mineralisation by osteoblast cells.
However, we can reasonably suppose that the ACP coating did
not remain amorphous during the 24 days of the cell culture exper-
iment at 37 C and erroneous conclusions could arise from ignoring
this possible evolution.
8.1.2. ACPs in low temperature and/or low energy coatings
Recently, research has focused on the development of new coat-
ing techniques that can overcome the main drawbacks associated
with HA coatings obtained by the plasma spraying technique, i.e.
low resorption, particle release and delamination, inhomogeneity
of the composition of the coating, no possibility of depositing ther-
mally unstable phases such as ACP, OCP or carbonated apatite anal-
ogous to bone mineral and no possibility of including bioactive
and/or therapeutic molecules in the coatings. The group of K. de
Groot in The Netherlands has active in the setting up and develop-
ment of biomimetic processes that enable the deposition of CaP
phases of biological interest.
Most coatings prepared at low temperatures have been ob-
tained using supersaturated calcium phosphate solutions [for
example simulated body fluid (SBF) solution], leading to CaP pre-
cipitation, mostly as apatite, onto the surface of metallic substrates
for dental or orthopaedic applications. The simplest way to pro-
mote heterogeneous nucleation of ACP on a metallic surface is to
control the supersaturation of the solution to adapt the conditions
to the nucleation properties of the metallic substrate. After an
induction period the metal becomes covered by a layer of CaP.
An amorphous carbonated CaP coating has been prepared at
37 C and pH 6 after soaking titanium alloy (TA6 V) disks for 24 h
in a calcium phosphate supersaturated solution saturated with
CO2 [112,113]. In this process a primary thin ACP coating formed
initially, with a carbonated apatite or OCP coating subsequently
being deposited on the ACP at 50 C. It is also possible to associate
such coatings with biologically active molecules. A similar biomi-
metic process involving soaking metallic discs in highly supersatu-
rated SBF solution (SBF  5) also led to a thin ACP coating, which
was subsequently soaked in a supersaturated calcium phosphate
solution including an antibiotic (tobramycin). This second step
led to a thick carbonated apatite layer containing tobramycin, on
the initial thin ACP deposit. The resulting antibiotic-loaded coating
was expected to reduce implant-associated infections by local re-
lease of this therapeutic agent [114]. This second step led to a thick
carbonated apatite coating containing tobramycin on the primary
thin ACP deposit.
Nagano et al. also used a biomimetic technique involving a
supersaturated calcium phosphate solution at 35 C to obtain an
ACP coating on polyethersulphone plates [115]. It took 12 days to
obtain a 20 lm thick ACP coating and 28 days for a 50 lm thick
one. They showed that newly formed bone grew in direct contact
with the implant as the coating degraded. However, we can expect
crystallisation of the ACP as apatite during this very slow deposi-
tion process (12–28 days), but the authors did not provide any fur-
ther details to support this point.
Even if all these biomimetic methods are simple, they have not
been adapted to mass production. Indeed, their main drawbacks
are related to slow deposition and the need for supersaturated
solutions, thereby raising storage and stability problems and mak-
ing them difficult to control on an industrial scale.
Other low temperature ACP coating techniques can be found in
the literature.
An electrochemical deposition method has been used by several
authors to prepare a thin film of metastable CaPs [116,117]. This
technique is based on water electrolysis, which induces a local in-
crease in pH at the cathode where the metal substrate to be coated
is placed. When the electrolysis bath contains a metastable cal-
cium and phosphate solution this pH rise increases the concentra-
tion of PO43 and local supersaturation of CaP salts. Under these
conditions homogeneous precipitation can occur at the cathode.
Using this technique at room temperature, Royer et al. obtained
a coating of amorphous calcium phosphate–carbonate with cracks
that could be related to the large amount of water associated with
the fresh precipitate and the shrinkage that occurred during dry-
ing. No cracks were observed when electrolysis was performed at
70 C, but these conditions favoured the direct deposition of poorly
crystalline biomimetic apatite [116].
Roessler et al. showed that ACP can be deposited on titanium
using an electrochemical technique at 36 C and pH 6.4. They con-
trolled the kinetics of ACP transformation to apatite by adjusting
the electrochemical parameters, such as current density (0.5 to
10 mA cm2) and time of polarisation (5 s–60 min) [117]. This
technique opens up the possibility of preparing biomimetic CaP
coatings of different solubilities by combining the more soluble
amorphous phase with poorly crystalline apatite. Even if character-
isation of coating adhesion was not performed in these studies, the
main drawbacks of the electrochemical technique are a slow rate of
deposition and poor adhesion of the coating to the metal surface.
Dutour Sikiric et al. recently reported a three-step method for
preparing a biomimetic organic–inorganic nanocomposite coatinginvolving ACP particles embedded in organic polyelectrolyte mul-
tilayers of poly-L-lysine and poly-L-glutamic acid as the first step
[118]. The second step is based on the in situ conversion of ACP
to OCP or poorly crystalline apatite when immersed in a metasta-
ble calcifying solution. Finally, deposition of a final polyelectrolyte
multilayer is performed in a third step leading to smoother sur-
faces which facilitate primary human osteoblast cell adhesion
and proliferation. Cell proliferation on nanocomposites with upper
polyelectrolyte multilayers was far superior than on any of the
individual components and was equivalent to proliferation on
the gold standard (plastics).
8.2. ACPs in hydraulic phosphocalcic bone cements
CaP cements have recently received considerable attention in
the field of bone substitutes. They form a mouldable paste that
can fit the shape of the bone defect perfectly, leading to hardened
bioactive materials favouring bone healing. In addition, some are
injectable, which enables the use of minimally invasive surgical
techniques for their implantation. However, CaP and ACP-based ce-
ments show slow resorption properties and low bone regeneration,
especially in cranioplasty [119].
The hardening of CaP cements is related to the entanglement of
CaP crystals formed by the hydrolysis of more soluble CaP phases
or acid–base reaction between two CaP compounds. However,
Driessens et al. reported an osteotransductive bone cement made
of ACP which set by a sol–gel transition [120].
It was thought that the high reactivity of ACPs in aqueous med-
ia, related to their relatively fast hydrolysis to apatite, would make
them good candidats as a reactive powder ingredient for bone ce-
ments [75,121]. However, the main problems related to the indus-
trial development of an ACP-based biomedical cement are the
hydrolysis rate, water content and stability of ACPs. The hydrolysis
rate has to be fast enough to allow hardening of the cement (typ-
ically between 10 and 30 min). The amount of water is crucial in
cements and the high water content of ACP might prevent harden-
ing. In addition, the lack of stability of ACPs might constitute a
problem for industrial processing and storage of the dry cement
ingredients (solid phase). A solution is to heat ACPs at 450 C to re-
move the excess water and stabilise the amorphous phase.
8.2.1. Physico-chemical properties of ACP-based cements
8.2.1.1. ACP–DCPD cements. There is only one ACP-based bone ce-
ment currently on the market, namely Biobon (a-BSM). This ce-
ment comprises a mixture of ACP (ATCP, 50 wt.%) and DCPD
(50 wt.%) which is mixed with an appropriate amount of aqueous
medium (deionised water or saline) with a liquid to solid ratio of
0.8 ml g1 at room temperature. An injectable paste is obtained
which sets in less than 20 min at 37 C. After hardening it is consti-
tuted of nanocrystalline apatite with crystal dimensions close to
those of human bone [122]. Other physico-chemical characterisa-
tions comfirmed the strong analogy of the end product with bone
mineral [123] and this ACP-based cement has been qualified as
‘biomimetic’ [124].
The setting of this cement was related to the rapid hydrolysis of
ACP to apatite, occurring within 20 min after mixing [124]. After
setting, slow hydrolysis of DCPD to apatite occurred in a second
step lasting up to 48 h after mixing [124]. These results have been
confirmed by FTIR spectroscopy and X-ray diffraction analyses (see
Figs. 10 and 11, respectively).
In this cement formulation DCPD crystals acted as seeds or tem-
plates to facilitate apatite nucleation and crystal growth; a sche-
matic representation of the ACP–DCPD cement setting and
hardening involving ACP and DCPD hydrolysis and HA crystallisa-
tion is presented in Fig. 12. The existence of an epitaxial relation-
ship between DCPD and apatite most likely favoured the
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Fig. 10. Conversion of ACP and DCPD into apatite as a function of time (per cent
apatite content) determined by mathematical decomposition of the m4 PO4 band
obtained by FTIR spectroscopy analysis. During the first 20 min a rapid increase is
assigned to the rapid hydrolysis of ACP at 37 C, corresponding to the hardening
time. A slow increase is assigned to the slow hydrolysis of DCPD (from [124] with
the kind permission of Trans Tech Publications).
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Fig. 13. Paste setting and hardening as a function of time at different temperatures.
The values represent the load (kg) required to penetrate 2 mm into the paste with a
1 mm diameter blunt ended needle [123].development of apatite crystals from the unstable amorphous
phase [125]. The setting and hardening of this ACP-based cement
is related to a conversion reaction strongly dependent on temper-
ature. The paste does not harden at room temperature and body
temperature is needed for the setting reaction to begin and devel-
op. This characteristic is an interesting advantage allowing an ex-
tended working time for the paste at room temperature and
linking setting to implantation. The dependence of hardening on10 20 30
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Fig. 11. X-ray diffraction diagrams (CoKa) of the cement during setting. The apatitic p
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Fig. 12. Schematic representation of the setting reaction of ACP–DCPD cements (a-BSM
after paste preparation. The hydrolysis of DCPD into apatite lasts longer (48 h).paste temperature can be clearly seen in Fig. 13, which shows
the evolution at different temperatures of the load required for a
1 mm diameter needle to penetrate 2 mm into the cement paste
[123].
Tofighi and Palazzolo have shown that mechano-chemical
grinding of the solid phase comprising DCPD and ACP modified
the powder characteristics [126]. The particle size of ACP and DCPD
was reduced within the first 2 h and DCPD became completely
amorphous after 24 h of co-grinding with ACP. Under these condi-
tions the kinetics of hardening of the cement were faster: the set-
ting time was 9 min when using 1 h milled powders and 3 min
when using 24 h milled powders (the setting time of the reference40 50 60
20 min
24 h
72 h
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hase forms rapidly in the first 20 mi, corresponding to the hardening time. DCPD
ind permission of Trans Tech Publications).
20 min 48 hours
ystals (platelets) Apatite crystals 
, Etex Corp.) involving rapid hydrolysis of ACP into apatite during the first 20 min
cement was 20 min). Co-grinding the powders also improved the
mechanical properties of the cement: 50 MPa when using 10 h
milled powders compared with 2.6 MPa for the reference cement
(unground powders).
Another way to improve the mechanical properties of ACP-con-
taining cements is based on the addition of water soluble polymers
to the cement paste. Mickiewicz et al. incorporated polyelectro-
lytes, polyethylene oxide and bovine serum albumin (BSA) into a
commercial ACP-based cement a-BSM) [127]. Polycation and
BSA addition led to increases in cement compressive strength of
six times and double, respectively, that of the reference cement.
These results correlated with the reduction in apatite crystallite
dimensions because of additive adsorption inhibiting crystal
growth.
Several authors have studied modified formulations of this ACP-
based cement, including additives with a view to improving and
controlling other properties, such as injectability [127,128]. In par-
ticular, setting time and injectability can be optimised for different
requirements by controlling the amount and nature of additives.
For example, the injectability of the paste can be improved by
preparing the paste with disodium phosphate solution as the liquid
phase, whereas the use of PEG, glycerine or citric acid solutions
have been shown to decrease the injectability of the paste and
shorten its setting time [127]. A compromise between appropriate
injectability and a sufficiently short setting time of ACP + DCPD ce-
ments always needs to be found to move towards minimally
invasive surgical procedures and avoid cement washout, a phe-
nomenon which generally occurs when the paste is in contact with
biological fluids. Wang et al. have studied the effect of introducing
natural macromolecules (chitosan, alginate and starch) as anti-
washout agents in ACP + DCPD formulations [128].
Owing to its biologically positive effects, especially on osteo-
blast cells, the introduction of strontium into ACP-based cements
has been studied by precipitating ACP by double decomposition
using a cationic solution containing strontium and calcium ions
[130]. Another way to introduce strontium into a cement is by
dry grinding strontium carbonate with the ACP–DCPD solid phase
[129]. A positive synergistic effect of the presence of SrCO3 has
been demonstrated on several properties of the cement, such as
an improvement in injectability of the paste, X-ray contrast
(radio-opacity) and mechanical properties of the hardened product
[129].
Recently, Yu et al. proposed an original ACP-based cement for-
mulation including mechano-activated b-cyclodextrins (CD)–ACP
and DCPD [86]. The mechano-activation of b-CD induced the for-
mation of hydrogen bonds between b-CD macromolecules, which
led to an increase in intermolecular interactions in the presence
of water. This could lead to a film of b-CD on the surface of the ce-
ment in contact with the aqueous medium without affecting the
setting reaction, beginning by the hydration of ACP–CD and DCPD
in the bulk of the cement. These authors have taken advantage of
this property to confer good anti-washout properties on an ACP-
based cement [86].
Speirs et al. have shown that a mixture of a-BSM cement and
morsellised bone is a promising composite with improved clinical
results in revision hip arthroplasty [131].
8.2.1.2. ACP–anhydrous dicalcium phosphate (DCPA) cements. An
ACP–DCPA cement with controlled crystallinity was proposed by
Wang et al. [132]. It consisted of a mixture of ACP and DCPA
(50 wt.%) with partially crystallised calcium phosphate (PCCP).
The latter compound was obtained by heating probably wet ACP
for 2 h at 450 C. The ratio of ACPto PCCP enabled control of the
crystallinity of the HA formed after setting and hardening and
the resorption properties of the cement. As in the case of the
ACP–DCPD cement, in the ACP–PCCP–DCPA cement the PCCP par-ticles acted as seeds to facilitate apatite nucleation and crystal
growth during setting. Consequently, a decrease in the setting time
was observed when the proportion of PCCP in the cement formula-
tion was increased.
8.2.1.3. Other ACP-containing cements. Van den Vreken et al. studied
the influence of ACP introduction on two phosphocalcic cement for-
mulations: an a-TCP-based cement and a TTCP–MCPM-based ce-
ment. They also prepared a pure ACP cement as a reference [133].
The authors showed that the addition of ACP to these cement formu-
lations led to a decrease in the crystallinity of the end product (apa-
tite), the setting time and the mechanical properties. They also
observed poor cell viability on the pure ACP cement.
As already mentioned in Section 7.2, Gbureck et al. presented an
original apatite cement system based on mechanically activated b-
TCP [88]. As already mentioned, prolonged milling treatment
(24 h) of crystalline b-TCP in ethanol induced a crystalline to ATCP
partial transformation. This partly ATCP powder led to a cement
which set within 5 min when mixed with sodium hydrogen phos-
phate (2.5%) solution. An increase in milling time resulted in a de-
crease in initial setting time and was attributed to the increase in
solubility of mechanically activated b-TCP. The authors pointed
out that after prolonged mechanical activation particle size was no
longer reducedbut themilling energy induced an increase in defects
within the crystal lattice and b-TCP thereby became partly
amorphous.
Brunner et al. studied several TCP-based CaP cements using dif-
ferent TCP crystalline (a-TCP and b-TCP) and/or amorphous phases
with powders of varying particle sizes as the starting materials
[134]. Cements prepared with pure nanosized ATCP particles
showed high reactivity and setting because of their rapid conver-
sion (in 30 min) into highly porous calcium-deficient HA with a
high specific surface area. Interestingly, the setting time was less
than 12 min when using ATCP particles of 25–60 nm size, but the
mechanical properties needed to be improved [135].
Mixtures of ATCP and a-TCP were been investigated by Brunner
et al., using nanosized and microsized milled reactive powders and
sodium phosphate buffer as the liquid phase [135].
The incorporation of ACP doped with ions of biological interest
(Mg2+, Zn2+ or F) in a cement formulation including a-TCP, MCPM
and b-TCP–HA granules was studied by Julien et al. [136]. Even if
the role of ACP in this system was not clearly explained by the
authors, the cement including ACP doped with fluoride showed a
shorter setting time and greater compressive strength than ce-
ments including ACP doped with zinc or magnesium.
8.2.2. ACP-based cements as drug delivery systems
Resorbable cements are attractive biomaterials as drug delivery
systems for antibiotics or growth factors for orthopaedic and den-
tal applications [137]. The association of rh-BMP-2, a protein
known to play a crucial role in the growth and regeneration of
bone tissue, with the injectable ACP-based cement a-BSM has
been shown to accelerate bone healing when injected in vivo
[138–140].
The association of the growth factor rh-BMP-2 with an ACP–
PCCP–DCPA cement has been shown to confer better early osteo-
conductive and osteoinductive properties on the cement [132].
8.3. ACPs in ceramics
The consolidation of ATCP has been investigated using cold ax-
ial compression (P = 400 MPa) or low temperature axial compres-
sion (400 MPa and T = 200 C for 24 h) [122]. No change in
composition and structure of the ACP was detected after each pro-
cess. However, the mechanical properties of the prepared ACP
ceramics were poor: in the case of cold axial compression the com-
pressive strength reached 21 MPa and the apparent density was
1.75, while the samples preheated at 200 C were not tested be-
cause they were too friable.
The possibility of preparing dense ceramics of ATCP was studied
by Drouet et al. using spark plasma sintering (SPS) at temperatures
ranging from 150 to 200 C; the SPS processing lasted less than
15 min [141]. These low temperature conditions are more adapted
to the processing of less stable phases such as ACP compared with
the experimental conditions in conventional sintering. Physico-
chemical characterisation of the prepared consolidated ceramics
indicated crystallisation of the initial ACP powder to an apatitic
phase with no other detectable crystalline phase. The microstruc-
ture of the prepared consolidated disks exhibited a large intergran-
ular porosity, which could explain the poor mechanical strength
observed (Brazilian test, r = 5 MPa for 6 min at 150 C). However,
an increase in the SPS processing time to 13 min led to a tensile
stress of r = 12 MPa, indicating the possibility of improving the
mechanical resistance of consolidated disks arising from SPS treat-
ment of ATCP.8.4. ACPs in composite biomaterials
Several composite biomaterials including ACPs have been stud-
ied and used, especially for dental applications. ACPs are involved
as a filler in ionomer cements (resins) used to fill cavities or as col-
loidal suspensions in toothpaste, chewing gum or mouthwash used
for the remineralisation of carious lesions and/or to prevent tooth
demineralisation [142–149]. These composites take advantage of
the ability of ACP to release calcium and phosphate ions, especially
in the acidic oral environment. These ions can take part in remin-
eralisation of enamel [147,150,151].
ACP can be incorporated into orthodontic adhesives, crown and
bridge adhesives, pit and fissure sealants and restorative compos-
ite resin. In these composite materials the ACP used is often Zr-
hybridised ACP or sometimes Si-hybridised ACP. As already men-
tioned in the Sections 5.3.2 and 7.1.1, the presence of certain ions
such as Zr2+ or SiO44 in ACP has been shown to delay its conver-
sion to apatite [152].
Polymer resins used as a matrix are photo-activated methacry-
late resins, for example mixtures of ethoxylated bisphenol A
dimethacrylate (EBPADMA), triethylene glycol dimethacrylate
(TEGDMA), hydroxyethyl methacrylate (HEMA) and methacryloyl-
oxyethyl phthalate (MEP) [151].
Several authors have shown that milling zirconia-hybridised
ACP improved the initial mechanical resistance of the composite
owing to a better interface and dispersion of ACP within the resin
matrix related to the desagglomeration and decrease in ACP parti-
cle size [153–155]. The mechanical response of milled ACP com-
posites when immersed in simulated saliva solution was closer
to that of glass-reinforced composites, and the authors observed
an increase in the incidence of a failure mode consistent with
stronger adhesion of milled ACP composites to dentin [154].
Casein phosphopeptide-stabilised ACP nanocomplexes and
fluoride-containing toothpastes and mouthwashes have demon-
strated anticariogenic activity in vitro and in vivo [147,150,156].9. Conclusion
ACPs offer a wide variety of compositions that can be found in
living organisms (especially invertebrates) or synthesised either
under biomimetic conditions or using high temperature/high en-
ergy techniques. ACP is easily converted into poorly crystalline
apatite analogous to bone mineral crystals and advantage can be
taken of its high reactivity to prepare bioactive biomaterials. ACP
is involved as a transient or constitutive phase in several commer-cial substitute bone materials, such as plasma sprayed coatings on
metal prostheses and injectable cements for orthopaedic applica-
tions. ACP is also used for dental applications as a filler in ionomer
cements to fill cavities or as a colloidal suspension in toothpastes,
chewing gums or mouthwashes to promote remineralisation of
carious lesions and/or to prevent tooth demineralisation.
Even if the instability of ACPs raises problems for mass produc-
tion, storage and processing that limit the development of ACP-
based biomaterials, the reactivity of ACP should certainly be fur-
ther exploited, especially to prepare coatings with enhanced adhe-
sion and bioactivity. In addition, we can take advantage of its ease
of assimilation in vivo to prepare composites with high remineral-
ising potential or drug carriers, even if its adsorption properties are
not well known.Appendix. Figures with essential colour discrimination
Certain figures in this article, particularly Figures 1, 3 and 12,
are difficult to interpret in black and white. The full colour images
can be found in the on-line version, at doi:10.1016/
j.actbio.2010.02.017.References
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